Information on CIN and NSF

Contrast media for renal patients and how to prevent CIN and NSF in these patients is a very topical issue.
 

European Medicines Agency 

European Medicines Agency makes recommendations to minimise risk of nephrogenic systemic fibrosis with gadolinium-containing contrast agents

FDA´s latest review 

FDA (The Food and Drug Administration) found the lowest risk of the skin disease, nephrogenic systemic fibrosis (NSF), was associated with Bracco's Prohance® and Multihance®.

NSF Trial

Bayer’s Magnevist, as well other gadolinium contrast dyes, including General Electric’s Omniscan and Covidien’s OptiMark, have been named in over 500 lawsuits filed by people who claim they or their loved ones developed NSF following exposure to one or more of the gadolinium-based MRI contrast dyes. For further information, please visit Newsinferno, or click on the link below.

Imaging renal offers webcasts

Two interesting webcasts within the field of CIN and NSF! The lectures include tips and advice on how to identify and treat this patient group. You also have the option to download handouts from the lectures.

The titles of the two lectures are:
- Identifying and Managing Patients with Chronic Kidney Disease by E. Kanal, R. Katzberg and R. Semelka.
- Imaging the Renally impaired Patient: Nephrogenic Systemic Fibrosis, by W. High
G. Saab and E. Kanal.

We still have the much valued lecture Imaging the renally impaired patient by Henrik S Thomsen, Denmark and Georges Saab, USA.

Log in to see these lectures, click here! 

Henrik S. Thomsen 

See Thomsen's presentation on CIN/NSF from X-ray Week 2008! Click on the file below.

We give you the opportunity to keep up-to-date on this topic. The links on the left give you guidelines and webcasts within this field.